Ramiro Castro-Santamaria

Ramiro Castro-Santamaria

Auto-generated profile, based on publicly available information

Ramiro Castro-Santamaria

King of Prussia, PA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2019 in International Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
PDF file
CCCourtney Crim
Courtney Crim
MWMichael L Watkins
Michael L Watkins
EBEric D Bateman
Eric D Bateman
GFGregory J Feldman
Gregory J Feldman
ISIsabelle Schenkenberger
Isabelle Schenkenberger
RCRamiro Castro-Santamaria
Ramiro Castro-Santamaria
Background: Batefenterol is a novel bifunctional muscarinic antagonist β2-agonist in development for COPD. The primary objective of this randomized, double-blind, placebo-controlled, active comparator, Phase IIb study was to model the dose–response of batefenterol and select a dose for Phase III development. Patients and methods: Patients aged ≥40 years with COPD and FEV1 ≥30% and ≤70% predicted normal were randomized equally to batefenterol 37.5, 75, 150, 300, or 600 µg, placebo, or umeclidinium/vilanterol (UMEC/VI) 62.5/25 µg once daily. The primary and secondary endpoints were weighted-mean FEV1 over 0–6 hours post-dose and trough FEV1, analyzed by Bayesian and maximum likelihood estimation Emax of dose–response modeling, respectively, on day 42. Results: In the intent-to-treat population (N=323), all batefenterol doses demonstrated statistically and clinically significant improvements from baseline vs placebo in the primary and secondary endpoints (191.1–292.8 and 182.2–244.8 mL, respectively), with a relatively flat dose–response. In the subgroup reversible to salbutamol, there were greater differences between batefenterol doses. Lung function improvements with batefenterol ≥150 µg were comparable with those with UMEC/VI. Batefenterol was well tolerated and no new safety signals were observed. Conclusion: Batefenterol 300 µg may represent the optimal dose for Phase III studies.

6 June 2018 in BJU International
Verified
Journal Article
Closed access
PDF file
AKAndrew G. Kuang
Andrew G. Kuang
JNJ. Curtis Nickel
J. Curtis Nickel
GAGerald L. Andriole
Gerald L. Andriole
RCRamiro Castro‐Santamaria
Ramiro Castro‐Santamaria
SFStephen J. Freedland
Stephen J. Freedland
DMDaniel M. Moreira
Daniel M. Moreira

1 July 2018 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
PDF file
EAEmma H Allott
Emma H Allott
SMSarah C. Markt
Sarah C. Markt
LHLauren E. Howard
Lauren E. Howard
AVAdriana C. Vidal
Adriana C. Vidal
DMDaniel M. Moreira
Daniel M. Moreira
SFStephen J. Freedland
Stephen J. Freedland
Background: Prostate cancer incidence rates vary 25-fold worldwide. Differences in PSA screening are largely, but not entirely, responsible. We examined geographic differences in prevalence of histologic prostate inflammation and subsequent prostate cancer risk. Methods: Seven thousand nonHispanic white men were enrolled in the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial from Europe (n = 4,644), North America (n = 1,746), South America (n = 466), and Australia/New Zealand (n = 144). Histologic inflammation in baseline negative prostate biopsies was classified as chronic (lymphocytes/macrophages) or acute (neutrophils). Multivariable logistic regression was used to examine associations between region and prostate inflammation, and between region and prostate cancer risk at 2-year biopsy. Results: Prevalence of prostate inflammation varied across region, with broadly similar patterns for acute and chronic inflammation. Relative to Europe, prevalence of acute inflammation was higher in North America [odds ratio (OR), 1.77; 95% confidence interval (CI), 1.51–2.08] and Australia/New Zealand (OR, 2.07; 95% CI, 1.40–3.06). Men from these regions had lower prostate cancer risk than Europeans at biopsy. Among North Americans, prevalence of acute inflammation was higher in Canada versus the United States (OR, 1.40; 95% CI, 1.07–1.83), but prostate cancer risk did not differ between these regions. Among Europeans, prevalence of acute inflammation was lower in Northern and Eastern (OR, 0.79; 95% CI, 0.65–0.97 and OR 0.62; 95% CI, 0.45–0.87, respectively), relative to Western Europe, and these men had higher prostate cancer risk at biopsy. Conclusions: Prevalence of histologic prostate inflammation varied by region. Geographic differences in prostate inflammation tracked inversely with geographic differences in prostate cancer risk. Impact: Characterization of premalignant prostate biology and the relationship with subsequent prostate cancer risk could inform prostate cancer prevention efforts. Cancer Epidemiol Biomarkers Prev; 27(7); 783–9. ©2018 AACR.

4 December 2017 in Prostate Cancer and Prostatic Diseases
Verified
Journal Article
Open access
PDF file
DMDaniel M. Moreira
Daniel M. Moreira
GAGerald L. Andriole
Gerald L. Andriole
RCRamiro Castro-Santamaria
Ramiro Castro-Santamaria
SFStephen J. Freedland
Stephen J. Freedland
Prostate atrophy (PA) is commonly identified in prostate biopsies. Previous studies suggest PA may be associated with lower PCa risk. However, it remains unclear whether PA is associated with smaller, less aggressive, and less advanced tumors. Thus, we sought to determine whether the presence and severity of baseline PA in men with initial biopsy negative for prostate cancer (PCa) is associated with PCa volume at 2- and 4-year repeat biopsy. We performed a retrospective analysis of 927 men 50–75-years-old with negative baseline biopsy and positive 2- or 4-year repeat biopsy for PCa in the Reduction by Dutasteride of PCa Events study. PA (present or absent), PA severity (mild or moderate/marked), and tumor volume were determined by central pathology. The association of baseline PA with repeat biopsy PCa volume was evaluated with linear and Poisson regressions in uni- and multivariable analyses. PA was identified in 559 (60%) baseline biopsies and was mild in 491 (88%) and moderate/marked in 68 (12%). PA was associated with larger prostate volumes (P < 0.001). At 2-year biopsy, PA was associated with lower overall mean total tumor volume (2.21 vs. 2.94 µL; P = 0.016), mean number of biopsy cores involved (1.85 vs. 2.08; P = 0.016), mean percent of cores involved (18.4% vs. 20.7%; P = 0.008), average core involvement (0.23 vs. 0.29 µL; P = 0.019) and overall mean percent tumor involvement (1.82% vs. 2.33%; P = 0.018). Similar results were found in multivariable analysis and analysis of 4-year repeat biopsies. Compared to mild PA, moderate/marked PA was associated with greater reduction in tumor volume. Amongst subjects with repeat prostate biopsy positive for PCa after negative baseline biopsy, the presence and severity of baseline PA were associated with lower PCa volume. This suggests PA may be associated with less aggressive PCa.

10 April 2017 in World Journal of Urology
Verified
Journal Article
Closed access
PDF file
DMDaniel M. Moreira
Daniel M. Moreira
GAGerald L. Andriole
Gerald L. Andriole
JNJ. Curtis Nickel
J. Curtis Nickel
CRClaus G. Roehrborn
Claus G. Roehrborn
RCRamiro Castro-Santamaria
Ramiro Castro-Santamaria
SFStephen J. Freedland
Stephen J. Freedland

30 April 2013 in Journal of Urology
Verified
Journal Article
Closed access
PDF file
DMDaniel Moreira
Daniel Moreira
JNJ. Curtis Nickel
J. Curtis Nickel
LGLeah Gerber
Leah Gerber
RMRoberto Muller
Roberto Muller
GAGerald Andriole
Gerald Andriole
SFStephen Freedland
Stephen Freedland
Cigarette smoking promotes systemic inflammation by increasing the levels of pro-inflammatory markers; however, its direct inflammatory effect on several organs is unknown. The prevalence of acute inflammation in prostate biopsies is estimated to be nearly 40%. The factors associated with inflammatory changes in the prostate of men undergoing biopsy are largely unknown. Therefore, we sought to evaluate the association of smoking status and acute inflammation in the prostate of men undergoing prostate biopsy.